Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 796

Sort by

Sort Order Select

Journal Articles

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Blood (2025) 146 (19): 2350–2356.

https://doi.org/10.1182/blood.2025028985

Published: 2025

Includes: Supplemental data

Journal Articles

Artificial intelligence in hematology

Aziz Nazha, Olivier Elemento, Sanjay Ahuja, Barbara Lam, Moses Miles, Roni Shouval, Shannon McWeeney, Shireen Sirhan, Andrew Srisuwananukorn, Torsten Haferlach

Blood (2025) 146 (19): 2283–2292.

https://doi.org/10.1182/blood.2025029876

Published: 2025

Journal Articles

Long-term event-free survival in patients with IGHV-mutated high-count monoclonal B-cell lymphocytosis and atypical, non-CLL-like phenotypes

Jan-Paul Bohn, Stephanie Grabenwarter, Leilu Mangold, Martyna Bartkowiak, Katrin Schweneker, Gregor Hoermann, Normann Steiner, Manuela Hoechstetter, Torsten Haferlach, Clemens-Martin Wendtner, Dominik Wolf

Blood (2025) 146 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2025-2112

Published: 2025

Journal Articles

Supporting routine diagnostics: AI for interpretation of interphase FISH images

Dennis Bode, Valerio Lupperger, Sven Maschek, Christian Pohlkamp, Torsten Haferlach, Isolde Summerer

Blood (2025) 146 (Supplement 1): 2577.

https://doi.org/10.1182/blood-2025-2577

Published: 2025

Journal Articles

Automated multi-source data consensus classification of low-frequency variants in hematologic malignancies using transparent artificial intelligence

Niroshan Nadarajah, Nanditha Mallesh, Kathrin Hildebrand, Wolfgang Kern, Torsten Haferlach

Blood (2025) 146 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2025-2576

Published: 2025

Journal Articles

Unlocking new frontiers in leukemia diagnostics through large language Model–Driven report generation

Vivian Wuerf, Christopher Maier, Benjamin Braun, Sven Maschek, Torsten Haferlach, Christian Pohlkamp

Blood (2025) 146 (Supplement 1): 2574.

https://doi.org/10.1182/blood-2025-2574

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Blood (2025) 146 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2025-3858

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

MDS without clonal marker: When depth outperforms breadth

Sandra Huber, Wencke Walter, Marietta Truger, Stephan Hutter, Heiko Mueller, Torsten Haferlach, Manja Meggendorfer

Blood (2025) 146 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2025-2071

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)

Blood (2025) 146 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2025-1453

Published: 2025

Journal Articles

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

Rainer Ordemann, Sandra Huber, Alessandro Baldi, Anna Stengel, Irene Fuhrmann, Christian Pohlkamp, Manja Meggendorfer, Sabit Delic, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann

Blood (2025) 146 (Supplement 1): 5248.

https://doi.org/10.1182/blood-2025-5248

Published: 2025

Journal Articles

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Blood (2025) 146 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2025-2084

Published: 2025

Journal Articles

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Blood (2025) 146 (Supplement 1): 396.

https://doi.org/10.1182/blood-2025-396

Published: 2025

Journal Articles

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient

Sybiryna Korenkova, Bogdan Medvedev, Arnold Ganser, Torsten Haferlach, Iryna Raus, Hans Kreipe, Isabel Sanchez-Ortega, Anna Sureda Balarí, Damiano Rondelli, Frank Maldarelli, Paul Rubinstein, Dietger Niederwieser

Blood (2025) 146 (Supplement 1): 7800.

https://doi.org/10.1182/blood-2025-7800

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Blood (2025) 146 (Supplement 1): 5785.

https://doi.org/10.1182/blood-2025-5785

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Artificial intelligence in hematology

Long-term event-free survival in patients with IGHV-mutated high-count monoclonal B-cell lymphocytosis and atypical, non-CLL-like phenotypes

Supporting routine diagnostics: AI for interpretation of interphase FISH images

Automated multi-source data consensus classification of low-frequency variants in hematologic malignancies using transparent artificial intelligence

Unlocking new frontiers in leukemia diagnostics through large language Model–Driven report generation

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

MDS without clonal marker: When depth outperforms breadth

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only